UFH Dosing for DVT Prophylaxis

Standard Prophylactic Dosing

The National Comprehensive Cancer Network recommends UFH 5000 IU subcutaneously every 8 hours for DVT prophylaxis in general surgery patients, as three times daily dosing was shown to be more effective than twice-daily administration in preventing DVT 1, 2
The National Comprehensive Cancer Network recommends UFH 5000 IU subcutaneously every 8 hours for DVT prophylaxis in cancer patients, as this is the specifically recommended regimen 1, 3
In ICU patients, UFH 5000 IU subcutaneously every 8 hours is recommended when LMWH is contraindicated or unavailable, as it provides a more consistent anticoagulant effect and reduces DVT incidence 4

A meta-analysis in general medical patients showed no difference in overall VTE rates between twice-daily versus three times daily dosing, according to the National Comprehensive Cancer Network 1
Twice-daily dosing showed less reduction in the combined endpoint of proximal DVT and PE, with a p-value of 0.05, as reported by the National Comprehensive Cancer Network 1
The risk of major bleeding was significantly higher with three times daily dosing, with a p-value of less than 0.001, which may favor twice-daily dosing in medical patients at higher bleeding risk, according to the National Comprehensive Cancer Network 1

UFH is the agent of choice for patients with creatinine clearance <30 mL/min, as it is primarily metabolized by the liver rather than renally excreted, according to the National Comprehensive Cancer Network and Praxis Medical Insights 1, 3, 4
Standard dosing of 5000 IU every 8 hours can be used without dose adjustment in renal failure, as recommended by Praxis Medical Insights 3, 4

The National Comprehensive Cancer Network advises against using UFH in patients with active or history of heparin-induced thrombocytopenia (HIT), and recommends using a direct thrombin inhibitor or fondaparinux instead 1
The Mayo Clinic Proceedings recommends monitoring platelet counts every 2-3 days from day 4 to day 14 in patients with HIT risk ≥1% 5
Praxis Medical Insights advises against administering anticoagulants too close to neuraxial anesthesia due to spinal hematoma risk 3
Praxis Medical Insights recommends against routinely monitoring anti-Xa levels for prophylactic dosing, as this is unnecessary for standard prophylaxis 3, 4

The National Comprehensive Cancer Network recommends UFH over LMWH in severe renal impairment (CrCl <30 mL/min) 1, 3, 4
The National Comprehensive Cancer Network recommends UFH over LMWH in patients without reliable IV access who cannot receive monitored therapeutic anticoagulation 1
Praxis Medical Insights recommends UFH over LMWH in settings where rapid reversibility is needed, though this is less relevant for prophylactic dosing 3
The Mayo Clinic Proceedings notes that LMWH is generally preferred over UFH when renal function is normal due to more predictable pharmacokinetics, reduced healthcare worker exposure, and lower rates of missed doses 5, 4